Thromb Haemost 2009; 101(03): 582-583
DOI: 10.1160/TH08-09-0596
Case Report
Schattauer GmbH

Acquired haemophilia A associated with transitory and severe factor V deficiency during bullous pemphigoid: First report

Anne Ryman
1   Haematology Laboratory, University Pellegrin Hospital, Bordeaux, France
,
Thomas Hubiche
2   Department of Dermatology, Saint-Andre Hospital, Bordeaux, France
,
Jean Amiral
3   Hyphen Biomed Laboratory, Neuville s/Oise, France
,
Alain Taïeb
2   Department of Dermatology, Saint-Andre Hospital, Bordeaux, France
,
Viviane Guerin
1   Haematology Laboratory, University Pellegrin Hospital, Bordeaux, France
› Author Affiliations
Further Information

Publication History

Received: 15 September 2008

Accepted after major revision: 27 February 2008

Publication Date:
24 November 2017 (online)

 

 
  • References

  • 1 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant; an update. Thromb Haemost 1995; 74: 1185-1190.
  • 2 Verbruggen B, Novakova I, Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
  • 3 Gupta S, Mahipal A. A case of acquired haemophilia associated with bullous pemphigoid. Am J Hematol 2007; 82: 502.
  • 4 Soria A, Matichard E, Descamps V. et al. Pemphigoïde et hémophilie acquise. Ann Dermatol Venereol 2007; 134: 353-356.
  • 5 Bryning S, Leslie J. Factor V inhibitor and bullous pemphigoid. Br Med J 1977; 2: 677-678.
  • 6 Suehisa E, Toku M, Atika N. et al. Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto’s disease and bullous pemphigoid. Thromb Res 1995; 77: 63-68.
  • 7 Patel RS, Harman KE, Nichols C. et al. Acquired haemophilia heralded by bleeding into the oral mucosa in a patient with bullous pemphigoid, rheumatoid arthritis and vitiligo. Postgrad Med J 2006; 82: e3.
  • 8 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F. et al. Acquired haemophilia : review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
  • 9 Guang-Sen Z, Wen-Li Z, Chong-Wen D. et al. Characterization of an acquired factor VIII inhibitor and plasmapheresis therapy in a patient with bullous pemphigoid. Thromb Haemost 2006; 96: 692-694.
  • 10 Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004; 2: 1082-1095.
  • 11 Nyfeler B, Kamiya Y, Boehlen F. et al. Deletion of 3 residues from the C-terminus of MCFD2 affects binding to ERGIC-53 and causes combined factor V and factor VIII deficiency. Blood 2008; 111: 1299-1301.